Prioritizing genes associated with prostate cancer development

被引:29
作者
Gorlov, Ivan P. [1 ]
Sircar, Kanishka [2 ]
Zhao, Hongya [1 ,5 ]
Maity, Sankar N. [1 ]
Navone, Nora M. [1 ]
Gorlova, Olga Y. [3 ]
Troncoso, Patricia [2 ]
Pettaway, Curtis A. [4 ]
Byun, Jin Young [1 ]
Logothetis, Christopher J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[5] Chinese Acad Sci, Inst Adv Comp & Digital Engn, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
基金
美国国家卫生研究院;
关键词
BREAST-CANCER; MICROARRAY DATA; EXPRESSION PROFILES; PROGNOSIS; DATABASE; LIMITS; TUMOR;
D O I
10.1186/1471-2407-10-599
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The genetic control of prostate cancer development is poorly understood. Large numbers of gene-expression datasets on different aspects of prostate tumorigenesis are available. We used these data to identify and prioritize candidate genes associated with the development of prostate cancer and bone metastases. Our working hypothesis was that combining meta-analyses on different but overlapping steps of prostate tumorigenesis will improve identification of genes associated with prostate cancer development. Methods: A Z score-based meta-analysis of gene-expression data was used to identify candidate genes associated with prostate cancer development. To put together different datasets, we conducted a meta-analysis on 3 levels that follow the natural history of prostate cancer development. For experimental verification of candidates, we used in silico validation as well as in-house gene-expression data. Results: Genes with experimental evidence of an association with prostate cancer development were overrepresented among our top candidates. The meta-analysis also identified a considerable number of novel candidate genes with no published evidence of a role in prostate cancer development. Functional annotation identified cytoskeleton, cell adhesion, extracellular matrix, and cell motility as the top functions associated with prostate cancer development. We identified 10 genes-CDC2, CCNA2, IGF1, EGR1, SRF, CTGF, CCL2, CAV1, SMAD4, and AURKA-that form hubs of the interaction network and therefore are likely to be primary drivers of prostate cancer development. Conclusions: By using this large 3-level meta-analysis of the gene-expression data to identify candidate genes associated with prostate cancer development, we have generated a list of candidate genes that may be a useful resource for researchers studying the molecular mechanisms underlying prostate cancer development.
引用
收藏
页数:8
相关论文
共 25 条
[21]   Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer [J].
Stanbrough, M ;
Bubley, GJ ;
Ross, K ;
Golub, TR ;
Rubin, MA ;
Penning, TM ;
Febbo, PG ;
Balk, SP .
CANCER RESEARCH, 2006, 66 (05) :2815-2825
[22]   Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray [J].
Wang, Long ;
Zhu, Jin-Shui ;
Song, Ming-Quan ;
Chen, Guo-Qiang ;
Chen, Jin-Lian .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (43) :6949-6954
[23]   Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation [J].
Yang, YH ;
Dudoit, S ;
Luu, P ;
Lin, DM ;
Peng, V ;
Ngai, J ;
Speed, TP .
NUCLEIC ACIDS RESEARCH, 2002, 30 (04) :e15
[24]   SNPs3D: Candidate gene and SNP selection for association studies [J].
Yue, P ;
Melamud, E ;
Moult, J .
BMC BIOINFORMATICS, 2006, 7 (1)
[25]   Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique [J].
Zigeuner, Richard ;
Droschl, Nikolaus ;
Tauber, Volkmar ;
Rehak, Peter ;
Langner, Cord .
UROLOGY, 2006, 68 (03) :518-522